Exploration of neoadjuvant chemotherapy for glioma

Abstract

Objective To explore the effects of ACNU combined with CDDP in malignant glioma treatment, and analyze the clinical validity and safety of drug combination, and to investigate theory evident for the clinical treatment with neoadjuvant chemotherapy. Methods (1) Analyzed the short-term effects and one year survival rate of ACNU and cisplatin intravenous infusion for 72 h and temozolomide (TMZ) chemotherapy retrospectively. (2)Assessed chemotherapy-related toxicity of different groups. Results (1)The short-term effect of ACNU and cisplatin combination chemotherapy was better than that of TMZ therapy, the partial response rate of the former was 56%, while the later was only 6%(P 0.05). (2)The myelosupression was higher in ACNU and cisplatin combination chemotherapy group (grade Ⅲ leucopenia and thrombocytopenia was 72% and 56% respectively)than that in TMZ therapy group(grade Ⅲ leucopenia and thrombocytopenia were all 0%), but it was tolerable. The other side effects including myelosuppression, damage of liver and kidney were all mild in both groups. Conclusions ACNU and cisplatin combination chemotherapy was not better than TMZ in one-year survival time or toxicity. But it showed special advantages in short-term effect which could reduce tumor invasion in a short time range. This made it more suitable for neoadjuvant chemotherapy to improve the total tumor removal rate and get lower recurrence rate. Key words: Glioma; Nimustine; Cisplatin; Neoadjuvant chemotherapy